9877 Stock Overview
A medical device company, engages in the research and development of interventional products for the treatment of structural heart diseases in the People’s Republic of China.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Jenscare Scientific Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$3.72 |
| 52 Week High | HK$44.20 |
| 52 Week Low | HK$3.17 |
| Beta | 0 |
| 11 Month Change | -6.77% |
| 3 Month Change | -22.18% |
| 1 Year Change | -89.33% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -90.47% |
Recent News & Updates
Recent updates
Shareholder Returns
| 9877 | HK Medical Equipment | HK Market | |
|---|---|---|---|
| 7D | 5.1% | -2.5% | -1.9% |
| 1Y | -89.3% | -52.8% | -6.7% |
Return vs Industry: 9877 underperformed the Hong Kong Medical Equipment industry which returned -52.8% over the past year.
Return vs Market: 9877 underperformed the Hong Kong Market which returned -6.7% over the past year.
Price Volatility
| 9877 volatility | |
|---|---|
| 9877 Average Weekly Movement | 7.0% |
| Medical Equipment Industry Average Movement | 6.9% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in HK Market | 14.1% |
| 10% least volatile stocks in HK Market | 3.6% |
Stable Share Price: 9877's share price has been volatile over the past 3 months.
Volatility Over Time: 9877's weekly volatility has decreased from 14% to 7% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 376 | Shiwen Lv | www.jenscare.com |
Jenscare Scientific Co., Ltd., a medical device company, engages in the research and development of interventional products for the treatment of structural heart diseases in the People’s Republic of China. It offers LuX-Valve and LuX-Valve Plus, a transcatheter tricuspid valve replacement (TTVR) product for the treatment of severe tricuspid regurgitation and high surgical risk; and Ken-Valve, a transcatheter aortic valve replacement product candidate for the treatment of severe aortic regurgitation or combined with aortic stenosis. The company also develops JensClip, a clip-based transcatheter mitral valve (TMVR) repair system, and JensRelive, a TMVR transfemoral system to treat patients with severe mitral regurgitation; MicroFlux, a transcatheter device to treat heart failure with pressured ejection fraction; and SimuLock, a bionics left atrial appendage occluder system for cardiogenic stroke prevention.
Jenscare Scientific Co., Ltd. Fundamentals Summary
| 9877 fundamental statistics | |
|---|---|
| Market cap | HK$1.55b |
| Earnings (TTM) | -HK$399.99m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.8x
P/E RatioIs 9877 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 9877 income statement (TTM) | |
|---|---|
| Revenue | CN¥0 |
| Cost of Revenue | CN¥0 |
| Gross Profit | CN¥0 |
| Other Expenses | CN¥371.74m |
| Earnings | -CN¥371.74m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.89 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 3.3% |
How did 9877 perform over the long term?
See historical performance and comparison